Loading...
Market
What will be the growth in GSK's oncology portfolio revenue in 2025?
2
Resolution / Starting Odds
Less than 5% increase • 25%
5% to 10% increase • 25%
10% to 15% increase • 25%
More than 15% increase • 25%
GSK's annual financial reports
Story
GSK Acquires IDRx for $1 Billion and $150 Million Earnout to Boost IDRX-42 for Gastrointestinal Cancers
Jan 13, 2025, 07:50 AM
GSK has announced its agreement to acquire IDRx, Inc., a clinical-stage biotech company based in Plymouth, Massachusetts, for an upfront payment of $1 billion. The deal, which could reach a total of $1.15 billion including potential milestone payments of up to $150 million, aims to enhance GSK's portfolio in cancer treatments. IDRx is currently developing IDRX-42, a drug in Phase 1 trials targeting gastrointestinal stromal tumors (GIST) and other gastrointestinal cancers. GSK's Chief Scientific Officer, Tony Wood, expressed enthusiasm for the early data from IDRX-42, highlighting its ability to address clinically relevant KIT mutations, which are a significant gap in current treatment options. This acquisition aligns with GSK's strategy to address critical patient needs in the oncology space.
View original story
Similar markets
Focus on internal development • 25%
Other strategic move • 25%
Another acquisition in oncology • 25%
Partnership with another biotech • 25%
Johnson & Johnson • 25%
Other • 25%
Roche • 25%
AstraZeneca • 25%
More than $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than 15% increase • 25%
Less than 5% increase • 25%
5% to 10% increase • 25%
10% to 15% increase • 25%
More than $2 billion • 25%
$500 million to $1 billion • 25%
Less than $500 million • 25%
$1 billion to $2 billion • 25%
Contributes less than 2% to revenue growth • 25%
No significant contribution • 25%
Contributes more than 5% to revenue growth • 25%
Contributes 2-5% to revenue growth • 25%
AstraZeneca • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
More than 30% • 25%
Less than 10% • 25%
10-20% • 25%
20-30% • 25%
$1 billion to $2 billion • 25%
Less than $1 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Increase by less than 10% • 25%
No significant increase • 25%
Increase between 10% and 20% • 25%
Increase by more than 20% • 25%